Edit Module
Bookmark and Share Email this page Email Print this page Print Pin It
Feed Feed

Pfizer decision propels Exact Sciences

Beginning in the fourth quarter, Pfizer one of the world’s largest pharmaceutical companies, will put its marketing muscle behind Madison-based Exact Sciences’ Cologuard at-home, DNA stool test for colorectal cancer. Exact Science’s stock jumped 26% immediately after the announcement.

According to an Exact Sciences release, Pfizer has signed an agreement through 2021 to co-promote Cologuard, the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Reportedly, the two companies will each invest $24 million next year to promote Cologuard.

In a Reuters report, Exact Sciences CEO Kevin Conroy says Pfizer will also receive 50% of gross profit above an agreed-upon baseline. The Madison company will continue marketing the product.

Add your comment:
Bookmark and Share Email this page Email Print this page Print Pin It
Feed Feed
Edit Module
Edit ModuleShow Tags

Events Calendar

Edit Module
Edit Module
Edit Module